Hi — I'm Alma
Hi — I'm Alma. I put this guide together for you because navigating kidney disease — and the world of clinical trials — can feel overwhelming. There's a lot of medical jargon, a lot of uncertainty, and sometimes not a lot of clear answers about what comes next.
I want to change that, at least a little. This article is a plain-language walkthrough of what's happening right now in nephrology research in the United States: what conditions are being studied, what kinds of treatments are in the pipeline, and how you might explore whether a clinical trial could be right for you or someone you care about.
You don't need a science degree to follow along. Let's take this one step at a time.
What is nephrology, and what conditions are we talking about?
Nephrology is the branch of medicine focused on the kidneys — those two fist-sized organs that filter your blood, balance fluids, and remove waste. When the kidneys' filtering units (called glomeruli) become damaged or inflamed, proteins and blood can leak into the urine, and kidney function can decline over time. This group of conditions is sometimes called glomerular disease, and it includes several specific diagnoses:
- IgA nephropathy (IgAN): The most common form of glomerulonephritis worldwide. It happens when an antibody called IgA builds up in the kidneys, causing inflammation and, over time, scarring. Some people have mild disease for years; others progress toward kidney failure.
- Focal segmental glomerulosclerosis (FSGS): In FSGS, some of the kidney's filtering units develop scar tissue. It can cause heavy protein loss in the urine (nephrotic syndrome), swelling, and progressive kidney damage. FSGS can be primary (arising on its own) or secondary (triggered by another condition).
- Membranous nephropathy (MN): Here, the immune system attacks the membranes in the kidney's filters, leading to protein leakage and, in many cases, nephrotic syndrome. Primary membranous nephropathy is autoimmune in nature; secondary forms can be linked to infections, medications, or other diseases.
- Minimal change disease (MCD): Named because the kidney tissue looks nearly normal under a standard microscope, MCD is the most common cause of nephrotic syndrome in children. It usually responds well to steroids, but relapses are common and some patients become steroid-resistant.
- ANCA-associated vasculitis: This is a group of autoimmune conditions where the immune system attacks small blood vessels, including those in the kidneys. When the kidneys are involved, it can cause rapidly progressive glomerulonephritis — a medical emergency that requires aggressive treatment.
- Lupus nephritis: When systemic lupus erythematosus (lupus) affects the kidneys, it's called lupus nephritis. It can range from mild to severe and is one of the most serious complications of lupus, sometimes leading to kidney failure if not managed well.
What ties all of these together is that they involve the immune system misbehaving in ways that damage the kidneys. Current treatments — steroids, immunosuppressants, blood pressure medications — help many patients, but they don't work for everyone and often come with significant side effects. That's exactly why research into new therapies matters so much.
What's happening in nephrology research right now
There's genuinely exciting momentum in kidney disease research. Right now, we're tracking 62 clinical trials in our nephrology scope across the United States. These span the full spectrum of development:
- Phase 1 and Phase 1/2 trials: 8 studies exploring early safety and dosing of new approaches
- Phase 2 trials: 20 studies — the largest group — testing whether new treatments actually work
- Phase 3 trials: 14 studies in late-stage testing, comparing new therapies head-to-head with existing standards of care
- Phase 4 and observational studies: 12 studies tracking long-term outcomes, natural disease history, and real-world data
The conditions getting the most attention are IgA nephropathy and FSGS, which together account for a large share of the active trials. Minimal change disease, membranous nephropathy, and ANCA-associated vasculitis also have meaningful research activity.
Several major organizations are driving this work:
- Novartis Pharmaceuticals is the most active sponsor in our data, with 8 trials. Notably, they're running a Phase 3 extension program studying iptacopan — a complement pathway inhibitor — in adults with primary IgA nephropathy. Complement-targeted therapies represent one of the most promising new drug classes in nephrology.
- Alexion Pharmaceuticals has 3 trials in our scope, continuing their focus on complement-mediated kidney diseases.
- The University of Michigan is running 4 studies, including the Nephrotic Syndrome Study Network (NEPTUNE), a landmark observational effort that's been building a precision-medicine framework for glomerular diseases like FSGS, MCD, and membranous nephropathy.
- The NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases) is sponsoring a Phase 2 trial combining rituximab and cyclosporine for idiopathic membranous nephropathy — exploring whether combining two immunomodulators works better than either alone.
- The NIAID (National Institute of Allergy and Infectious Diseases) is testing belimumab plus rituximab versus rituximab alone for primary membranous nephropathy — a strategy that targets B cells from two different angles.
- Kaneka Medical America is studying the Liposorber® LA-15 system, an apheresis device for drug-resistant FSGS — a completely different approach from medication, using blood filtration to remove disease-causing factors.
- Other sponsors like Amgen, Biogen, Nkarta (exploring cell-based therapies), Northwell Health (testing vagus nerve stimulation for steroid-resistant nephrotic syndrome in children), and Dimerix Bioscience (running a pivotal Phase 3 trial for FSGS) round out a diverse research landscape.
What stands out is the variety of mechanisms being studied: complement inhibitors, B-cell–targeting biologics, JAK-STAT inhibitors, apheresis devices, and even neuromodulation. Nephrology research is moving well beyond "more steroids, more immunosuppression."
What this means for you as a patient
If you're living with one of these kidney conditions — especially if your current treatment isn't working well, or if you're dealing with tough side effects — a clinical trial might be worth exploring. That doesn't mean it's the right move for everyone, and it certainly doesn't mean you'd be a "guinea pig." It means you'd have access to a treatment that isn't yet available to the general public, under close medical supervision.
Here are some questions worth asking yourself and your care team:
- Is my current treatment controlling my disease? If you're still losing significant protein in your urine, or your kidney function is declining despite therapy, a trial studying a new mechanism might offer something your current regimen can't.
- What are the potential benefits and risks? Every trial has a detailed informed consent process. You should understand what the study drug does, what side effects have been seen so far, and whether there's a chance you'd receive a placebo.
- What's the time commitment? Some trials require frequent clinic visits, blood draws, or biopsies. Make sure the logistics are realistic for your life.
- Will my nephrologist support this? Ideally, your kidney doctor and the trial team work together. Your doctor's input matters.
- Can I leave if I want to? Yes — always. Participation is voluntary, and you can withdraw at any time.
Clinical trials aren't a last resort. For many of the conditions in this article, trials represent the most innovative care available today.
How our triage works
I built Alma's triage to make finding the right trial simpler. When you visit our nephrology page, you'll be guided through a short chat — no forms, no walls of text.
Here's what happens:
- You'll answer a few questions about your diagnosis, where you're located, and what matters to you.
- Alma matches your answers against our curated set of 62 nephrology trials currently enrolling in the United States.
- You'll see a shortlist of studies that may fit your situation, with plain-language summaries.
- If something looks promising, we'll point you toward the next step — whether that's contacting the study site or talking to your doctor.
We don't collect your data to sell it. We don't push you toward any particular trial. The goal is simply to help you find what's out there — clearly and honestly.
Ready to explore?
If you're curious whether there's a nephrology trial that fits your situation, the best next step is a quick, low-pressure triage conversation.
Start the triage here → almastudies.com/nephrology
You don't need to commit to anything. You just need to be willing to explore. I'll be here to help you make sense of what you find.